BACKGROUND: Retrospective accounts suggest that therapeutic doses of paracetamol can produce severe hepatic injury in patients with putative high-risk conditions, including alcoholism and infectious hepatitis. Metabolism of paracetamol to its hepatotoxic metabolite is enhanced in patients who abuse alcohol, who also have compromised liver defences from depressed hepatic glutathione. AIM: To determine the effect of paracetamol on serum liver tests of newly abstinent subjects who abuse alcohol, including subjects with hepatitis C infection. METHODS: A randomized, double-blind, placebo-controlled study. Adult alcohol abusers with a current drinking episode longer than 7 days received eitherplacebo or paracetamol 4 g/day for 5 days. RESULTS: Of 142 subjects enrolled, 74 receivedparacetamol and 68 received placebo. Mean ALT activity during treatment increased from 48 to 62 IU/L in the paracetamol group and from 47 to 49 IU/L in the placebo group. Maximum ALT was 238 and 249 IU/L in the paracetamol and control groups respectively. The INR remained unchanged and serum bilirubin decreased in both groups. Subgroup analyses for subjects with alcoholic hepatitis, hepatitis C virus antibody and other subgroups showed no statistical difference between groups. CONCLUSION: Administration of paracetamol 4 g/day appears safe in newly abstinent patients who abuse alcohol.
RCT Entities:
BACKGROUND: Retrospective accounts suggest that therapeutic doses of paracetamol can produce severe hepatic injury in patients with putative high-risk conditions, including alcoholism and infectious hepatitis. Metabolism of paracetamol to its hepatotoxic metabolite is enhanced in patients who abuse alcohol, who also have compromised liver defences from depressed hepaticglutathione. AIM: To determine the effect of paracetamol on serum liver tests of newly abstinent subjects who abuse alcohol, including subjects with hepatitis C infection. METHODS: A randomized, double-blind, placebo-controlled study. Adult alcohol abusers with a current drinking episode longer than 7 days received either placebo or paracetamol 4 g/day for 5 days. RESULTS: Of 142 subjects enrolled, 74 received paracetamol and 68 received placebo. Mean ALT activity during treatment increased from 48 to 62 IU/L in the paracetamol group and from 47 to 49 IU/L in the placebo group. Maximum ALT was 238 and 249 IU/L in the paracetamol and control groups respectively. The INR remained unchanged and serum bilirubin decreased in both groups. Subgroup analyses for subjects with alcoholic hepatitis, hepatitis C virus antibody and other subgroups showed no statistical difference between groups. CONCLUSION: Administration of paracetamol 4 g/day appears safe in newly abstinent patients who abuse alcohol.
Authors: Angela Christina Busch; Meenakshi Denduluri; Joseph Glass; Scott Hetzel; Shalu P Gugnani; Michele Gassman; Dean Krahn; Brienna Deyo; Randall Brown Journal: Alcohol Clin Exp Res Date: 2017-06-12 Impact factor: 3.455
Authors: Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott Journal: Inflammopharmacology Date: 2013-05-30 Impact factor: 4.473
Authors: Takeki Uehara; Oksana Kosyk; Emmanuelle Jeannot; Blair U Bradford; Katherine Tech; Jeffrey M Macdonald; Gary A Boorman; Saurabh Chatterjee; Ronald P Mason; Stepan B Melnyk; Volodymyr P Tryndyak; Igor P Pogribny; Ivan Rusyn Journal: Toxicol Appl Pharmacol Date: 2012-11-29 Impact factor: 4.219
Authors: Barry Rumack; Kennon Heard; Jody Green; Donald Albert; Becki Bucher-Bartelson; Michael Bodmer; Marco L A Sivilotti; Richard C Dart Journal: Pharmacotherapy Date: 2012-07-31 Impact factor: 4.705
Authors: Kennon J Heard; Jody L Green; Laura P James; Bryan S Judge; Liza Zolot; Sean Rhyee; Richard C Dart Journal: BMC Gastroenterol Date: 2011-03-14 Impact factor: 3.067